Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema, Semaglutide and Cagrilintide in Obesity
NCT07527195Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cagrilintide and semaglutide in obesity (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in insulin-stimulated fluorodeoxyglucose (FDG) uptake in skeletal muscle at 51 weeks. Started Apr 2026; status: recruiting.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07527195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527195.